Osimertinib in Resected EGFR-Mutated NSCLC

被引：1

作者：

Tsuboi, Masahiro ^{[1
]}

Herbst, Roy S. ^{[2
]}

Wu, Yi-Long ^{[3
]}

机构：

[1] Natl Canc Ctr Hosp East, Kashiwa, Japan

[2] Yale Canc Ctr, New Haven, CT 06510 USA

[3] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 389卷 / 14期

关键词：

D O I：

10.1056/NEJMc2309385

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To the Editor: The results of the final analysis of the ADAURA trial, reported by Tsuboi et al. (July 13 issue),(1) show a relevant benefit in overall survival among patients with resected non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation who received adjuvant osimertinib. It is disappointing that less than half of the patients in the control group who had a relapse actually received osimertinib as the first subsequent treatment. The authors explain that this was due to the double-blind design, because the amendment allowing open-label osimertinib was implemented only after the primary analysis. Thus, many patients . . .

引用

页码：1341 / 1342

页数：2

共 50 条

[1] Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Tsuboi, Masahiro
Herbst, Roy S.
John, Thomas
Kato, Terufumi
Majem, Margarita
Grohe, Christian
Wang, Jie
Goldman, Jonathan W.
Lu, Shun
Su, Wu-Chou
de Marinis, Filippo
Shepherd, Frances A.
Lee, Ki Hyeong
Le, Nhieu Thi
Dechaphunkul, Arunee
Kowalski, Dariusz
Poole, Lynne
Bolanos, Ana
Rukazenkov, Yuri
Wu, Yi-Long
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 137 - 147
[2] Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Masahiro Tsuboi
Roy S. Herbst
Thomas John
Terufumi Kato
Margarita Majem
Christian Grohé
Jie Wang
Jonathan W. Goldman
Shun Lu
Filippo de Marinis
Frances A. Shepherd
Ki Hyeong Lee
Nhieu Thi Le
Arunee Dechaphunkul
Dariusz Kowalski
Laura Bonanno
Manuel Dómine
Lynne Poole
Ana Bolanos
Yuri Rukazenkov
Yi-Long Wu
[J]. Targeted Oncology, 2024, 19 : 131 - 134
[3] Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Tsuboi, Masahiro
Herbst, Roy S.
John, Thomas
Kato, Terufumi
Majem, Margarita
Grohe, Christian
Wang, Jie
Goldman, Jonathan W.
Lu, Shun
de Marinis, Filippo
Shepherd, Frances A.
Lee, Ki Hyeong
Le, Nhieu Thi
Dechaphunkul, Arunee
Kowalski, Dariusz
Bonanno, Laura
Domine, Manuel
Poole, Lynne
Bolanos, Ana
Rukazenkov, Yuri
Wu, Yi-Long
[J]. TARGETED ONCOLOGY, 2024, 19 (02) : 131 - 134
[4] Osimertinib in EGFR-Mutated Advanced NSCLC
Staege, Martin S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (19): : 1863 - +
[5] CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC
Gourd, Elizabeth
[J]. LANCET ONCOLOGY, 2018, 19 (10): : E516 - E516
[6] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
Planchard, D.
Janne, P. A.
Cheng, Y.
Yang, J. C. -H.
Yanagitani, N.
Kim, S-W
Sugawara, S.
Yu, Y.
Fan, Y.
Geater, S. L.
Laktionov, K.
Lee, C. K.
Valdiviezo, N.
Ahmed, S.
Maurel, J-M
Andrasina, I
Goldman, J.
Ghiorghiu, D.
Rukazenkov, Y.
Todd, A.
Kobayashi, K.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (21): : 1935 - 1948
[7] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Ramalingam, S. S.
Vansteenkiste, J.
Planchard, D.
Cho, B. C.
Gray, J. E.
Ohe, Y.
Zhou, C.
Reungwetwattana, T.
Cheng, Y.
Chewaskulyong, B.
Shah, R.
Cobo, M.
Lee, K. H.
Cheema, P.
Tiseo, M.
John, T.
Lin, M-C
Imamura, F.
Kurata, T.
Todd, A.
Hodge, R.
Saggese, M.
Rukazenkov, Y.
Soria, J-C
Boyer, Michael
Lee, Chee
Hughes, Brett
O'Byrne, Kenneth
Briggs, Peter
Milward, Michael
John, Thomas
Demedts, Ingel
Vansteenkiste, Johan
Bustin, Frederique
Barrios, Carlos Henrique
Timcheva, Constanta
Butts, Charles
Goss, Glenwood
Juergens, Rosalyn
Leighl, Natasha
Cheng, Susanna
Burkes, Ronald
Zhou, Caicun
Zhang, Helong
Shu, Yongqian
Cheng, Ying
Zhou, Qing
Li, Wei
Feng, Guosheng
He, Yong
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 41 - 50
[8] Osimertinib also improves overall survival in EGFR-mutated NSCLC
Lichert, Frank
[J]. PNEUMOLOGIE, 2024, 78 (03): : 143 - 143
[9] Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
Jiang, Tao
Xu, Xiaobo
Chen, Xiaojuan
Ding, Ning
Hu, Qin
Zhou, Caicun
Hu, Jie
[J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2514 - 2517
[10] Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
Lu, Shun
Kato, Terufumi
Dong, Xiaorong
Ahn, Myung-Ju
Quang, Le-Van
Soparattanapaisarn, Nopadol
Inoue, Takako
Wang, Chih-Liang
Huang, Meijuan
Yang, James Chih-Hsin
Cobo, Manuel
Oezgueroglu, Mustafa
Casarini, Ignacio
Khiem, Dang-Van
Sriuranpong, Virote
Cronemberger, Eduardo
Takahashi, Toshiaki
Runglodvatana, Yotsawaj
Chen, Ming
Huang, Xiangning
Grainger, Ellie
Ghiorghiu, Dana
van der Gronde, Toon
Ramalingam, Suresh S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024,

← 1 2 3 4 5 →